Clinical Trial Update: Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring ex vivo TCR αβ T cell depletion to prevent graft-versus-host disease after mismatched donor peripheral blood stem cell transpla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hematologic Malignancy | Phase 2 | Status: TERMINATED | Results posted: 2022-05-10